Thalidomide treatment reduces the alteration of paracellular barrier function in mice ileum during experimental colitis

Shock

Volumn 25, Issue 5, 2006, Pages 515-521

  Mazzon, Emanuela ^b   Cuzzocrea, Salvatore ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b NONE

Author keywords

Dinitrobenzene sulfonic acid; Inflammation; Intestinal permeability; TJ protein; TNF

Indexed keywords

LANTHANUM; NITRATE; NITROBENZENE DERIVATIVE; SULFONIC ACID DERIVATIVE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; ILEUM; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; MOUSE; NONHUMAN; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; COLITIS; DINITROBENZENES; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; ILEUM; IMMUNOSUPPRESSIVE AGENTS; LANTHANUM; MEMBRANE PROTEINS; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; PERMEABILITY; PHOSPHOPROTEINS; SULFONIC ACIDS; THALIDOMIDE; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646802344     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000209556.31457.e7     Document Type: Article

References (34)

1. Heiskala M, Peterson PA, Yang Y: The roles of claudin superfamily proteins in paracellular transport. Traffic 2:93-98, 2001.
2. Gassler N, Rohr C, Schneider A, Kartenbeck J, Bach A, Obermuller N, Otto HF, Autschbach F: Inflammatory bowel disease is associated with changes of enterocytic junctions. Am J Physiol Gastrointest Liver Physiol 281:G216-G228, 2001.
3. Singh AB, Harris RC: Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells. J Biol Chem 279:3543-3552, 2004.
4. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. J Immunol 163:380-386, 1999.
5. Mazzon E, Muia C, Di Paola R, Genovese T, De Sarro A, Cuzzocrea S: Thalidomide treatment reduces colon injury induced by experimental colitis. Shock 23:556-564, 2005.
6. Wettstein AR, Meagher AP: Thalidomide in Crohn's disease. Lancet 350:1445-1446, 1997.
7. Bauditz J, Wedel S, Lochs H: Thalidomide reduces tumor necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50:196-200, 2002.
8. Murphy GJ, Holder JC: PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21:469-474, 2000.
9. Kolios G, Valatas V, Ward SG: Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 113:427-437, 2004.
10. Diaz-Granados N, Howe K, Lu J, McKay DM: Dextran sulfate sodium -induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 156:2169-2177, 2000.
11. Alnadjim Z, Kayali Z, Haddad W, Holmes EW, Keshavarzian A, Mittal N, Ivancic D, Koehler R, Goldsmith D, Waltenbaugh C, et al: Barrett differential effects of T-cell activation on gastric and small bowel permeability in alcohol-consuming mice. Alcohol Clin Exp Res 26:1436-1443, 2002.
12. Cuzzocrea S, Dugo L, Patel NS, Di Paola R, Cockerill GW, Genovese T, Thiemermann C: High-density lipoproteins reduce the intestinal damage associated with ischemia/reperfusion and colitis. Shock 21(4):342-351, 2004.
13. Holm AL, Bowers KE, McMeekin TO, Gaspari AA: Chronic cutaneous lupus erythematosus treated with thalidomide. Arch Dermatol 129:1548-1550, 1993.
14. Lora L, Mazzon E, Martines D, Fries W, Muraca M, Martin A, d'Odorico A, Naccarato R, Citi S: Hepatocyte tight-junctional permeability is increased in rat experimental colitis. Gastroenterology 113:1347-1354, 1997.
15. Cuzzocrea S, Rossi A, Mazzon E, Di Paola R, Genovese T, Muia C, Caputi AP, Sautebin L: 5-Lipoxygenase modulates colitis through the regulation of adhesion molecule expression and neutrophil migration. Lab Invest 85:808-822, 2005.
16. Cuzzocrea S: Emerging biotherapies for inflammatory bowel disease. Expert Opin Emerg Drugs 8:339-347, 2003.
17. Elson CO: Experimental models of intestinal inflammation: new insights into mechanisms of mucosal homeostasis. In Ogro PL, Lamm ME, Bienenstock J, Mestecky J, Strober W, McGhee JR (eds.): Mucosal Immunology. San Diego: Academic Press, pp 1007-1024, 1999.
18. Snapper SB, Rosen FS, Mizoguchi E, Cohen P, Khan W, Liu CH, Hagemann TL, Kwan SP, Ferrini R, Davidson L, et al: Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity 9:81-91, 1998.
19. Matsumoto S, Okabe Y, Setoyama H, Takayama K, Ohtsuka J, Funahashi H, Imaoka A, Okada Y, Umesaki Y: Inflammatory bowel disease-like enteritis caecitis in a senescence accelerated mouse P1/Yit strain. Gut 43:71-78, 1998.
20. Blumberg RS, Saubermann LJ, Strober W: Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 11:648-656, 1999.
21. Cuzzocrea S, McDonald MC, Mazzon E, Mota-Filipe H, Lepore V, Ciccolo A, Terranova ML, Britti D, Caputi AP, Thiemermann C: The tyrosine kinase inhibitor tyrphostin AG 126 reduced the development of colitis in the rat. Lab Invest 80:1439-1453, 2000.
22. Mazzon E, Puzzolo D, Caputi AP, Cuzzocrea S: Role of IL-10 in hepatocyte tight junction alteration in mouse model of experimental colitis. Mol Med 8:353-366, 2002.
23. Irvine EJ, Marshall JK: Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk. Gastroenterology 119:1740-1744, 2000.
24. Lilja I, Gustafson-Svard C, Franzen L, Sjodahl R: Tumor necrosis factor-α in ileal mast cells in patients with Crohn's disease. Digestion 61:68-76, 2000.
25. Schmitz H, Rokos K, Florian P, Gitter AH, Fromm M, Scholz P, Ullrich R, Zeitz M, Pauli G, Schulzke JD: Supernatants of HIV-infected immune cells affect the barrier function of human HT-29/B6 intestinal epithelial cells. AIDS 16:983-991, 2002.
26. Fries W, Mazzon E, Squarzoni S, Martin A, Martines D, Micali A, Sturniolo GC, Citi S, Longo G: Experimental colitis increases small intestine permeability in the rat. Lab Invest 79:49-57, 1999.
27. Fallon MB, Brecher AR, Balda MS, Matter K, Anderson JM: Altered hepatic localization and expression of occludin after common bile duct ligation. Am J Physiol 269:C1057-C1062, 1995.
28. Fallon MB, Gorelick FS, Anderson JM, Mennone A, Saluja A, Steer ML: Effect of cerulein hyperstimulation on the paracellular barrier of rat exocrine pancreas. Gastroenterology 108:1863-1872, 1995.
29. D'Inca R, Di Leo V, Corrao G, Martines D, D'Odorico A, Mestriner C, Venturi C, Longo G, Sturniolo GC: Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 94:2956-2960, 1999.
30. Bojarski C, Gitter AH, Bendfeldt K, Mankertz J, Schmitz H, Wagner S, Fromm M, Schulzke JD: Permeability of human HT-29/B6 colonic epithelium as a function of apoptosis. J Physiol 535:541-552, 2001.
31. Gitter AH, Wullstein F, Fromm M, Schulzke JD: Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 121:1320-1328, 2001.
32. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, : A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411:603-606, 2001.
33. Zareie M, Singh PK, Irvine EJ, Sherman PM, McKay DM, Perdue MH: Monocyte/macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn's disease. Am J Pathol 158:1101-1109, 2001.
34. Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK: CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124:993-1000, 2003.